We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GEN Genuit Group Plc

5.50 (1.19%)
22 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genuit Group Plc LSE:GEN London Ordinary Share GB00BKRC5K31 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  5.50 1.19% 466.00 438,463 16:35:19
Bid Price Offer Price High Price Low Price Open Price
462.00 465.00 468.00 459.00 468.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Plastics Pipe 586.5M 38.5M 0.1551 29.72 1.14B
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:19 AT 1,702 466.00 GBX

Genuit (GEN) Latest News

Genuit (GEN) Discussions and Chat

Genuit Forums and Chat

Date Time Title Posts
05/4/202307:45Genuit Group56
19/11/200619:49GEN - SILLY PRICE500
26/8/200405:32Watching closely-
07/8/200314:33Anyone here invested in Generics?3
10/4/200217:16Further gloom for Generics UK4

Add a New Thread

Genuit (GEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-05-22 15:35:19466.001,7027,931.32AT
2024-05-22 15:35:19466.008583,998.28AT
2024-05-22 15:35:19466.00101,833474,541.78UT
2024-05-22 15:29:55461.0014.61AT
2024-05-22 15:29:25462.00168776.16AT

Genuit (GEN) Top Chat Posts

Top Posts
Posted at 16/8/2022 14:40 by km18
Genuit posted Interims for the 6 months ended June 30th 2022 this morning. The Group performed reasonably in the HY period with revenues up 7.6% to £318m, PBT down 2.7% to £32.9m and EPS up 27.6% to 10.1p. According to Joe Vorih, CEO, “Agile pricing leadership offset inflationary pressures, and the effect of selective business decisions helped to increase our margins. While mindful of the macroeconomic pressures, we have good momentum as we enter the second half, and the Group anticipates meeting full year expectations.” These are for high single digit revenue growth and widening margins. However, consensus market estimates for FY22 EPS at 33.7p look too aggressive. Valuation is also a little unhelpful with forward PE ratio at 12.4x in the bottom quartile for the sector. Share price is also still in a 12-month correction for now. GEN is a share to monitor for now...

...from WealthOracle
Posted at 18/2/2022 13:37 by km18
...from last year...

Company overview:
Genuit Group is actually the new name of Polypipe Group plc. They provide sustainable solutions for water, climate and ventilation management. Sustainability is at the core of the firm’s strategy, driven by constant innovations. Genuit benefits from the active plans of governments across the globe to achieve net zero strategies and promote ESG activities and foresees geographic reach to be a major driver of growth for the group in the long term.
Blended approach for growth, with several acquisitions and continuous Capex seems to be working for the company in the long run, as both revenues and EPS have been growing steadily over the past 6 years, with the sole exception the catharsis of 2020. Fundamentally the company is also supported by a solid history of debt retirement and cash generation.
the half-year report sounds very promising. The group revenue was 32.5% above the 2019 figure (yes, that is a 3rd above the covid free year), driven by a significant raise in residential business at £183.8m (64% growth yoy lfl basis). The sole red flag on the report comes in the face of pressured margins, coming from the rising input costs. This has been balanced very nicely by 8% increase in prices for final customers, which proves the company’s brand recognition.  The labour supply issues several sectors are experiencing seems to be fading at Genuit, but we suggest keeping your eyes open for September for further guidance on the direction of the “pingdemic”. Genuit’s exposure to pen air projects is what supported the performance during the lockdowns, but the group saw drop in the commercial side of the sector. So, overall growth there is mediocre at 8.3%. Analyst consensus is expecting 9% increase in profit, built on the residentials and the acquisitions which are performing quite well. The board is expecting “underlying operating profit for FY to be ahead of expectations”....from WealthOracleAM
Posted at 16/11/2021 15:43 by scooper72
Looks like Aberdeen Standard Investments who hold 10.96 percent have cut their holding by about 10 percent and sold 2.3M shares last month. And I guess there must be others with large holding taking some profits. I'm now down an annoying 14 percent on my current holding in my SIPP having sold out previously at 688p with my original larger holding in my ISA. But thinking it is a bit late to comfortably take the £300 loss without worrying about doubly kicking myself if the price recovers. Today's drop seems hard to understand when considering the results out this morning looked ok
Posted at 16/11/2021 10:29 by dope007
Input costs are definitely not past their peak. Additionally the industry is seeing further raw material shortage issues.

Order books are full but at some point these horrendous input price rises are going to lead to reducing orders. However Genuit are in a better place than the window boys with less reliance on the home replacement mkt were at some point a home owner is going to say nope, not paying that...
Posted at 16/11/2021 08:32 by scooper72
Do you see these factors averaging out in terms of when they announce their profits or do you see the share price pulling back further on results whenever they come out. Ok kicking myself for going back in a bit early and just wondering where fair value is currently.
Posted at 13/10/2021 13:12 by dope007
Like the rest of our industry 2 dynamics are at play

1) Raw mat massive price hikes and ongoing/rolling shortages

2) High demand so selling everything they can produce even at higher prices
Posted at 19/8/2021 10:49 by philanderer
Yesterday's Deutsche note..

(Sharecast News) - Analysts at Deutsche Bank raised their target price on plastic piping manufacturer Genuit from 653.0p to 708.0p on Wednesday, citing the group's "strong" first-half performance

Deutsche Bank pointed to Genuit's adjusted interim operating profit of £48.6m, eclipsing its 2019 first-half performance by roughly 24% as it primary reason for the upgrade but also noted that the company appeared to be continuing to trade well, prompting a rise in management's expectations for the full year.

"We raise our 2021-2023E operating profit forecasts by 4-7% and our target price by circa 8%," said the German bank, which also reiterated its 'buy' rating on the stock.

"The company remains a strong performer, with recent acquisitions operating at or above expectations (three in February alone indicative of a team that does not let the grass grow under its feet)."
Posted at 18/8/2021 14:08 by philanderer
Keyno, it seems to be bouncing back. Maybe helped by this?

Genuit Group: Deutsche Bank keeps at buy and raises target price from 653.0p to 708.0p.
Posted at 24/5/2021 18:40 by philanderer
Genuit Group: Berenberg reiterates hold with a target price of 630p.
Posted at 30/8/2005 08:19 by ariane
Interim Results

RNS Number:5593Q
Generics Group AG
30 August 2005

30 August 2005



Generics, a leading integrated technology consulting, development and investment
organisation, today announces its results for the six months to 30 June 2005.


* Turnover increased by 28% to #10.7m (H1 2004: #8.3m)
* Consulting and IP exploitation activities reported operating profit of
#0.3m (H1 2004 loss of #0.1m) while increasing fee income by 34%
* Operating loss for the Group of #0.9m (H1 2004 loss of #2.1m) after
expensed costs of spinouts of #0.6m
* Portfolio BVCA valuation of #12.5m (Q1 2005: #11.9m)
* Cash balance of #3.6m (Q4 2004: #5.1m) before proceeds of #1.05m from
the disposal of Imerge Ltd
* Generics' spinout CMR Fuel Cells Ltd received the 2005 Carbon Trust
award as Innovator of the year and in addition was a winner of the
Individual and Small Business of the Year category
* Successful completions of #4m financing by Sphere Medical Holding Ltd,
originally Generics' medical device joint venture with Siemens, and #2.3m
financing by CMR Fuel Cells Ltd
* Launch of SGAI Tech Ltd, Scientific Generics' Hong Kong based joint
* Adjusted losses per share of 0.5 pence (2004 loss of 1.0 pence)
* Net assets per share of 8.7p per share (H1 2004: 9.4p) before taking
into account the BVCA portfolio valuation uplift equivalent to 3.5p per
share (H1 2004: 3.0p)

On 11 August 2005 Generics announced that it had completed the sale of its
shareholding in Imerge Limited. The consideration included a cash payment of
#1.05m, and future incentive payments dependent upon performance. The BVCA
valuation for Generics' share of Imerge at Q1 2005 was #1.3m.

Johan Bjorklund, Generics' Chairman, commented:

"I am pleased with both the development of the group during the first six months
and the progress in the consulting and IP exploitation activities in particular.
Our core technology development and consulting activity grew significantly,
increasing fee income by 34% year-on-year whilst achieving a good and increasing
profitability. SGAI Tech, our Hong Kong based joint venture, is performing ahead
of forecast, adding new clients to its initial customer, Hornby plc. Income from
licensing and royalty activities will improve with the next AutosheathTM
milestone payment of $0.5m expected in the second half. While Q3 is likely to
see a moderate seasonal reduction in revenue and sales run-rate, the order book
and sales processes are now strong enough to sustain the ongoing growth in the
technology consulting and IP business.

Within our venturing activity during the first half we have received industry
accolades for our spinout companies, CMR Fuel Cells Ltd and Sphere Medical
Holding Ltd, both of which have been successfully financed in the year to date.
Various funding, IPO and disposal opportunities continue to be developed across
the portfolio. The prospects for CMR and Sphere, in particular, are strong."

The Generics Group AG (44) 1223 875200
Martin Frost
Simon Davey
Genuit share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock